Scavenging the hidden impacts of non-coding RNAs in multiple sclerosis

Aya A. Elkhodiry, Hend M. El Tayebi*

Molecular Pharmacology Research Group, Department of Pharmacology, Toxicology and Clinical Pharmacy, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt

1. Introduction into MS

Multiple sclerosis (MS) is a chronic neuroinflammatory disease that causes severe neurological dysfunction leading to disabilities in patients. The prevalence of the disease has been increasing gradually worldwide, and the specific etiology behind the disease is not yet fully understood. Therapies aimed at treating MS patients have been growing lately, intending to delay the disease progression and increase the patients’ quality of life. Various pathways play crucial roles in developing the disease, and several therapeutic approaches have been tackling those pathways. However, these strategies have shown several side effects and inconsistent efficacy. MicroRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) are known to act as key players in various disease pathogenesis and development. Several proinflammatory and anti-inflammatory miRNAs have been reported to participate in the development of MS. Hence, this review assesses the role of miRNAs, lncRNAs, and circRNAs in regulating immune cell functions better to understand their impact on the molecular mechanics of MS.

Multiple sclerosis (MS) is a chronic neuroinflammatory disease that causes severe neurological dysfunction leading to disabilities in patients. The prevalence of the disease has been increasing gradually worldwide, and the specific etiology behind the disease is not yet fully understood. Therapies aimed at treating MS patients have been growing lately, intending to delay the disease progression and increase the patients’ quality of life. Various pathways play crucial roles in developing the disease, and several therapeutic approaches have been tackling those pathways. However, these strategies have shown several side effects and inconsistent efficacy. MicroRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs) have been shown to act as key players in various disease pathogenesis and development. Several proinflammatory and anti-inflammatory miRNAs have been reported to participate in the development of MS. Hence, this review assesses the role of miRNAs, lncRNAs, and circRNAs in regulating immune cell functions better to understand their impact on the molecular mechanics of MS.

1. Introduction into MS

Multiple sclerosis (MS) is one of the most common neurological disorders and a leading cause of non-traumatic disability in young adults in many countries [1]. The disease is more common in adults than children, with an incidence peak between the age of 20 and 40, and incidence rates usually decrease after the age of 50, with women twice at risk of the disease than men. As per the systemic analysis done during the Global burden of disease study in 2016, an estimated 2.2 million people worldwide had MS corresponding to a prevalence rate of 30.1 per 100,000 [2]. The etiology of MS is quite complex and, to a great extent, unpredictable as well. It is suspected to be a multi-component disease mediated by the infection-induced autoimmune process superimposed on genetic predisposition. A various number of aetiopathogenetic factors have been identified to play a role in MS, including genetic susceptibility, smoking, exposure to the Epstein-Barr virus (EBV), low exposure to sunlight (presumed to be mediated through vitamin D insufficiency), obesity, high salt intake and sedentary lifestyle [3].

Concluding an accurate description of the clinical phenotype of a typical MS case is essential for treatment decisions and prognosis. Initially, in 1996, the US National Multiple Sclerosis Society (NMSS) Advisory Committee classified MS disease into four main subtypes: Relapsing-remitting (RR), secondary progressive (SP), primary progressive (PP), and progressive relapsing (PR) [4]. However, the committee decided to revisit this phenotyping as it lacked objective biological support. In 2014, the International Advisory Committee on Clinical Trials of MS updated the previous classification of MS subtypes based on recently identified clinical aspects, imaging, biological markers, activity, and progression. The new MS classification divides the clinical courses into four main subtypes: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS) [5]. Experimental autoimmune encephalomyelitis (EAE) is the commonly used experimental model for MS [6]. The model is usually induced by active immunization with myelin-derived proteins or by passive transfer of activated myelin-specific CD4+ T lymphocytes [7]. Like MS in human patients, EAE is characterized by paralysis caused by CNS inflammation, demyelination of neurons, axonal damage, and neurodegeneration. Some EAE models exhibit remission and relapse (relapsing-remitting EAE) while other models represent chronic EAE state making them similar to human disease. This review focuses on the role of non-coding RNAs (ncRNAs) in regulating immune cells and immune pathways responsible for MS pathogenesis. This review tackles miRNAs, lncRNAs and circRNAs as common regulatory non-coding RNAs (ncRNAs) modulating the expression of other genes/proteins. The impact of miRNAs and lncRNAs in MS pathogenesis has been extensively reviewed previously.

* Corresponding author.
E-mail address: hend.saber@guc.edu.eg (H.M. El Tayebi).

https://doi.org/10.1016/j.ncrna.2021.12.002
Received 21 October 2021; Received in revised form 3 December 2021; Accepted 5 December 2021
Available online 7 December 2021
2068-0540/© 2021 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nevertheless, this review reports data investigating different models (MS patients and EAE) involving different samples (blood, serum, cerebrospinal fluid (CSF), oligodendrocytes, brain tissue) and reporting information regarding the method of assessment or the experimental design used in the involved studies. Finally, the review worked on exploring and concluding the possible interplay or areas of overlap between miRNAs and lncRNAs regulations and addressed the possible reasons for results discrepancies among reported data from different studies.

The research was conducted at the States National Library of Medicine (PubMed) to achieve the proposed goal. For the search in databases, the descriptors used were: “non-coding RNAs” or “microRNAs” or “miRNAs” or “lncRNAs” or “long non-coding RNA,” “circRNA,” and “Multiple sclerosis.” Research papers, books, and published data were reviewed for relevance to the review’s aim and summarized. The selection was made by reading abstracts first and then reading full-text articles to relevant publications. Criteria for inclusion were: complete, relevant publication, available online, in English, without a limit of the publication date, with detailed information about participants, methods, and analyses. Criteria for exclusion: duplicate publication and out-of-scope publications. Data abstracted were in the form of descriptive information, covering the type of samples used, type of patients, techniques, and findings or effects reported. Bias was limited by evaluating the studies through their internal validity rather than the conclusion.

2. Molecular pathogenesis of MS

MS is an idiopathic chronic inflammatory demyelinating disease of the central nervous system (CNS) with distinct numerous demyelinating lesions known as plaques. The exact etiopathogenesis of the disease is complex but known to be a mix of genetic, environmental, and immune factors [8]. Regarding the immunopathogenesis of MS, it is proposed to be a myelin-specific T cell attack that initiates an inflammatory process resulting in CNS demyelination. In 1986, the available facts led to the hypothesis that MS develops under the influence of a combination of factors causing demyelination in the CNS. These factors are (1) a genetically susceptible individual, (2) an environmental event resulting in a symptomless systemic illness, probably immune-mediator initiator, (3) a subsequent alteration of the blood-brain barrier (BBB), (4) a myelinoclastic plaque-forming mechanism in the CNS [9]. The pathogenesis has been reviewed extensively since then, and Fig. 1 simplifies the immune pathogenesis of the disease from peripheral activation leading to the destruction of the myelin sheath.

3. What are non-coding RNAs

Non-coding RNAs (ncRNAs) are RNA species beyond messenger RNA that appear to include a layer of internal signals that regulate various gene expression levels. The regulation could be chromatin architecture/epigenetic memory, transcription, RNA splicing, editing, translation, and turnover. These regulations may dictate most human complex characteristics and play a role in disease and genetic variation within

---

**Fig. 1.** Schematic diagram of possible pathogenesis of multiple sclerosis. Lymphocytes activated in the periphery by a particular event will bypass the blood-brain barrier. Initially, they bind with the cell adhesion molecules present on the capillary endothelium and gain access into the brain. Once inside, the reactive cells activate the immune cell traffic (T-and B-cells) and mediate the devastating cascade. Cytotoxic T-cells release perforins and granzymes, and activated B-cells produce antibodies against the myelin sheath, thus mediating the demyelination process. Abbreviations: BBB, Blood-brain barrier, CNS, Central Nervous System, PRF, Perforin, GZMB, Granzyme B, NO, Nitric Oxide, ROS, Reactive Oxygen Species.
and between species [10]. According to function, ncRNAs are classified into two major categories: regulatory and structural ncRNAs [11]. Structural ncRNAs are rRNA and tRNA, while regulatory ncRNAs are further divided into three classes according to their sizes into small, medium, and lncRNAs, as illustrated in Fig. 2, showing the detailed classification of non-coding RNAs.

4. MicroRNAs

MiRNAs account for 1–5% of the human genome and regulate at least 30% of protein-coding genes [12,13]. It is known that miRNA plays a vital role in regulating gene expression hence modulating diverse cellular and metabolic pathways; however, the specific targets of miRNAs are not yet fully known [14]. They are small, evolutionary conserved, single-stranded, non-coding RNA molecules of less than 30 nucleotides in size. They usually bind to their target mRNA by base-pairing inhibiting protein production by either degradation or inhibition of translation of the mRNA [15]. Mature miRNA is generated through two-step cleavage of primary miRNA (pri-miRNA), which incorporates into the effector complex RISC. The degree of complementarity between the miRNA and mRNA dictates which silencing mechanism is employed [16].

4.1. Biogenesis

MiRNAs are derived from the double-stranded region of 60–70 nucleotides RNA hairpin precursor [17]. miRNAs are transcribed by RNA polymerase II or III generating pri-miRNA molecule, which is processed by the microprocessor complex comprised of DGCR8 and Drosha into precursor miRNA (pre-miRNA). This pre-miRNA is then exported to the cytoplasm in a nucleocytoplasmic transporter containing Exportin 5 and Ran-GTP. Following export, pre-miRNA is cleaved by Dicer to give miRNA duplex. This miRNA duplex releases the mature miRNA to assemble into the RISC loading complex consisting of Ago2, TRBP, PACT, and Dicer directing the silencing of the target mRNA through RNA interference (RNAi) [16]. Gene silencing could be at transcriptional

Fig. 2. Classification of non-coding RNAs.

Fig. 2 classifies non-coding RNAs into Regulatory and structural according to their functions. Further classification of regulatory ncRNAs occurs according to their size into small, medium, and long ncRNAs, while structural ncRNAs only have rRNAs and tRNAs.
gene silencing (TGS) or post-transcriptional gene silencing (PTGS) levels [18]. The TGS targets DNA by altering promoter or enhancer efficiencies, the methylation status of genes, and deleting gene sequences [19]. On the other hand, PTGS mechanisms rely on the breakdown of mRNA by using antisense RNA, ribozymes, DNases, miRNAs, and RNAi. RNAi is utilized to determine gene function and as part of therapeutic intervention to downregulate the expression of genes playing a role in disease pathogenesis [20]. Fig. 3 illustrates miRNA biogenesis and how it regulates mRNA expressions.

4.2. Beginning of miRNA research in MS

Multiple studies investigate the role of miRNAs in MS as it is suggested they are involved in the pathogenesis of MS. They are studied in circulation, brain tissues, immune cells, and CSF. The first miRNAs that were shown to be dysregulated in MS are miR-18b, miR-493, and miR-599 in patients experiencing a relapse compared to controls [21]. In the second study, miR-17 and miR-20a were discovered to be down-regulated in MS patients and are known to regulate genes accompanied by T cell activation [22]. miR-145 was discovered in the third study and was seen to be the best single disease-specific miRNA marker with a specificity of 89.5% and sensitivity of 90% [23] and was discovered to decrease during disease transition from RRMS to SPMS [24, 25]. The subsequent study was able to distinguish between different subsets of cells and showed that miR-17-5p was upregulated in CD4+ T cells which correlated with changes in the expression of probable target genes of miR-17-5p as phosphatase and tensin homology (PTEN) and phosphatidylinositol-3-kinase (PI3K) regulatory subunit 1 [26, 27]. The following study studied the expression of miR-34a, miR-155, and miR-326 in MS lesions and were found upregulated in active lesions compared to inactive ones. These miRNAs are thought to target and reduce CD47 in brain resident cells, causing the release of macrophages from inhibitory controls [28]. The following study identified 23 miRNAs differentially expressed in CD4+CD25 high T regulatory cells from MS patients compared to controls. miR-106b and miR-25 had higher T-reg/T-effector cell ratios in MS patients, and they worked at silencing the TGF-β signaling pathway involved in the differentiation and maturation of T-regulatory cells [29].

4.3. MiRNAs in EAE, human brain tissue, and blood-brain barrier

4.3.1. EAE

MiR-326 was correlated with disease severity in EAE mice and MS patients. Using the EAE model; silencing miR-326 led to fewer Th17 producing cells and milder EAE, while the overexpression caused the opposite effect by inhibiting Ets-1; a negative regulator of Th17 differentiation [30, 31]. MiR-23b was significantly under-expressed in the acute phase of EAE, and ectopic overexpression led to a defect in leukocyte migration and resistance to EAE. Further investigations showed that it suppresses leukocyte migration through targeting CCL7; the adoptive transfer of miR-23b decreased EAE severity as it inhibited the migration of pathogenic T cells to the CNS [32]. In reactive astrocytes, miR-409-3p and miR-1896 simultaneously induce the production of inflammatory cytokines via SOCS3/STAT3 pathway, enhancing chemotaxis of CD4+ T cells and worsening EAE [33]. miR-140-5p was found downregulated in CD4+ T cells of EAE mice and inversely related with disease progression and its overexpression inhibited Th1 cell development through the mitochondrial respiratory pathway, STAT1 hypermethylation, and GATA3 demethylation [34]. A recent study on EAE mice showed that the knockout of miR-17-92 and miR-106b protected against neuroinflammation through the downregulation of inflammatory cytokines in the spinal cord of double knockout mice and a decrease in Th17 cells [35]. miR-134-3p is found protective in MS as its overexpression in MS rats enhanced mitochondrial activity of neurons and CD34+ cells proliferation and decreased cytochrome c content, inflammatory response, and cell apoptosis, all through inhibiting serine protease 57 (PRSS57) [36]. An interesting study reported the critical role of miR-125a-5p in regulating vitamin D receptor activity in EAE as its inhibition blocked the decrease of VDRs in the spinal cord of EAE mice and hence a new probable therapeutic intervention [37].

MiRNAs have been reported to play an essential role in disease remyelination, a crucial repair process that highly affects disease course [38]. Hence, the research into the mechanisms of miRNAs in MS is of great importance as they are a new avenue for targeted therapeutic approaches. miR-125a-3p is prominently upregulated in the active lesion of MS patients and OPCs (oligodendrocyte precursor cells) isolated from EAE mice, and this negatively affects remyelination through its direct interaction with Scl8a3 sodium-calcium membrane transporter; necessary for oligodendrocyte maturation [39]. Moreover,
miR-27a is a crucial regulator of oligodendrocyte development as increased levels of miR-27a leads to loss of myelination and remyelination, inhibition of OPCs proliferation through cell cycle arrest, and dysregulation of Wnt B-catenin signaling pathway [40].

4.3.2. Brain tissues/blood-brain barrier

Another set of studies looked at the brain tissues of MS patients where miRNA-125a-5p was found to play a role in BBB integrity. Its overexpression increases BBB tightness with thicker and more consistent tight junctions formed by vascular endothelial-cadherin (VE-cadherin) and zona-occuludent-1 [41]. A mentioned earlier, miR-125a-3p was reported upregulated in active lesions of MS patients and negatively affects oligodendrocyte maturation [39]. A study on Iranian MS patients reported an increased expression of miR-142 isoforms in the white matter of MS patients and the spinal cord of EAE mice that could contribute to MS pathogenesis by interacting with SOCS1 and TGFβR1 [42].

4.4. Circulating exRNAs

4.4.1. CSF of MS patients

A study on CSF of MS patients showed consistent upregulation in miR-21 and miR-146a-5p in Gd+ MS patients directly related to the number of Gd+ lesions; hence they represent a valuable biomarker for active MS lesions [43]. A large class III evidence study confirmed the upregulation of miR-181c and miR-663; they possess high diagnostic value in CSF of MS patients compared to patients with other neurologic disorders [44].

4.4.2. Serum/plasma of MS patients

Some studies researched the differential expression of miRNAs in plasma/serum of various classes of MS patients where miR-92a-1* was seen to be elevated in the plasma of RRMS patients compared to controls or SPMS patients. This miRNA’s level could negatively correlate to disease duration and disability score, and according to ingenuity pathway analysis (IPA), it was predicted that miR-92 could target CD40 directly on immune cells and affect CD40 signaling [24]. The same study showed that let-7a was severely decreased in SPMS patients and could target Toll-Like Receptor 4 (TLR4) and TLR9 as well as Interleukin (IL-12Rb2) and transforming growth factor-beta receptor 2 (TGF-βR2) as per IPA analysis [24]. Moreover, Let-7i was significantly increased in serum exosomes of MS patients. It was suggested to inhibit T regulatory cell induction via targeting insulin-like growth factor-beta receptor 1 (IGF1R) and transforming growth factor-beta receptor 1 (TGFBR1) as their expression is reduced in CD4+ T cells of MS patients [45]. A study on Egyptian patients showed significant downregulation of miR-300 and miR-450b-5p expression in serum samples of RRMS and SPMS patients compared to healthy controls, strengthening their use as possible biomarkers for disease progression [46]. Serum miR-128-3p is reported inversely proportional to relapse rate as it was found to be upregulated in progressive compared to relapsing patients and higher in patients without relapses after sample collection than patients who experienced relapse [47]. Another study confirmed the upregulation of miR-155 and miR-146a in serum samples of MS patients compared to healthy controls and pointed that they are directly related to patients’ EDSS and disease pathogenesis [48]. All these studies shine the light on new promising non-invasive biomarkers for disease activity that can be explored on larger cohorts.

4.4.3. Peripheral blood of MS patients

Most other studies looked for miRNA expression in peripheral blood immune cells. A study identified miRNA dysregulation in PBMCs of MS patients and concluded that miR-let-7d, miR-744, miR-93, miR-326, miR-21, miR-146a, miR-142-3p, miR-145, miR-146b, miR-200c and miR-125a were up-regulated while miR-328, miR-152, miR-199a, miR-1-let-7g, miR-15a, miR-16-1 and miR-140-5p were down-regulated in MS patients compared to controls. By building a network of miRNAs and their susceptibility genes, they found that KRAS (an important MS susceptibility gene) is a possible target of miR-199a and that miR-142-3p could target IL7R and KRAS genes. These data suggest that miR-199a and miR-142-3p might act as MS therapeutic targets in the MAPK/JAK-STAT signaling pathway [49]. Using microarray analysis, a study by Yang et al. identified that miR-30a, miR-93, miR-20b, and miR-20a might be key players in MS pathogenesis. It also revealed that miR-328-3p was upregulated in MS patients targeting RAC2 that had downregulated tendency in MS while miR-20a-5p had upregulated tendency and its downstream target gene EIF4EBP2 also had the down-regulated tendency in MS patients [50]. A study by Martinelli-Boneschi et al. showed a significant decrease in miR-150 and miR-let-7g expression in MS and tried to identify their target genes, concluding that let-7g could target TLR4 and HIV-1 Tat interactive protein 2 (HTATIP2 or TIP30), which is usually overexpressed in MS chronic lesions. At the same time, miR-150 was found to target SOCS1, SPI1, and ephrinB2 (EPHB2) involved in the maturation of the immune system [51]. A study focusing on miRNA expression profile in PBMCs of SPMS patients confirmed the downregulation of miR-21-5p, miR-26b-5p, miR-29b-3p, miR-142-3p, and miR-155-5p and revealed that SOCS6 is targeted by most of the dysregulated miRNAs in SPMS patients, which are upregulated in their CD4+ T cells and are involved in T cell activation regulation [52].

A study investigating the expression of prominent miRNAs in monocytes isolated from RRMS and PPMS patients reported upregulation of miR-146a, miR-223, miR-125a, miR-30c, and miR-23a in both patients’ subtypes as compared to controls. miR-485 and miR-708 were reported significantly downregulated in RRMS patients compared to controls which correlated with upregulation of mRNA levels of survivin in CD4+ T cells. This could explain the role of these mRNA in regulating apoptosis and, therefore, the persistent inflammatory milieu in MS patients [53]. While miR-181a was augmented in RRMS but not in PPMS patients compared to healthy controls, miR-124 was reduced in PPMS patients compared to controls and RRMS patients. Interestingly, miR-155 was found decreased in RRMS and PPMS patients compared to controls [54]. This increase in anti-inflammatory miRNAs and decrease in proinflammatory miRNAs in monocytes raises the idea that monocytes establish an anti-inflammatory/pro-regenerative response in MS or fluctuate through two distinct phenotypes during the disease course. Tables 1 and 2 summarize miRNAs in MS, showing their target proteins or pathways and their use as potential disease biomarkers.

Several miRNAs were found to enhance Th17 differentiation through different pathways. MiR-let-7e, miR-144, miR-155, miR-182, miR-183c, miR-200a, miR-233, miR-326, miR-384, miR-448, and miR-590 were found to increase Th17 differentiation through regulating various pathways such as IL-10 pathway, mTOR, Foxo1, IL-17, IFN-γ, HIF1α, PTPN2, tol1, CXCL3 and IL23R illustrated in Fig. 4. On the contrary, another group of miRNAs was found to modulate Th17 differentiation, including miR-let-7, miR-let-7f-5p, miR-15b, miR-20b, miR-26a, miR-132, miR-146, miR-301a, and miR-384 through regulating pathways and proteins such as STAT3, O-linked N-acetyl glucosamine transferase (OGT), RORγT, IL-6, IL7, IFN-γ, IL-21, IL1r1, II32r, CRC2, CCR5 and PIAS3 as illustrated in Fig. 4 as well. Moreover, patients with MS have reduced expression of TGFβ signaling, reducing the ability of CD4+ T cells to differentiate into T regulatory cells. The differential expression of miRNAs in those patients could be linked to the impaired TGFβ pathway. MiR-26a and miR-182 were reported to contribute to Treg differentiation through regulating Foxp3, as shown in Fig. 5. In addition, the TGFβ pathway was seen to be regulated by several miRNAs such as miR-let-7a, miR-let-7b, miR-let-7i, miR-21, miR-25, miR-27b, miR-106b, miR-128, miR-141, miR-142, miR-181c, miR-200a, and miR-500a leading to T regulatory cell differentiation as presented in Fig. 5 as well.
Table 1 lists the differentially expressed miRNAs in MS research stating their presence of the study.

| miRNA | Expression | Pathway | Experiment | Reference |
|-------|------------|---------|------------|-----------|
| miR-125a-5p | High (plasma) | BBB integrity | In vitro | [41] |
| miR-92a-1* | Low | CD40 targeting | In vitro | [24] |
| miR-let-7a | Low | TLR4 and TLR9 | In vitro | [24] |
| miR-145 | Low | Disease Transition | In vivo | [23,24] |
| miR-17, miR-20a | Low | T cell activation | In vitro | [22] |
| miR-17-5p | High (CD4+ T cells) | PTEN and PISK regulatory subunit 1 | In vitro and In vivo | [26,27] |
| miR-34a, miR-155, miR-326 | High (active lesions) | CD47 on brain resident cells; macrophage activation | In vitro and In vivo | [28] |
| miR-106b, miR-25 | High (CD127 low Tregs) | Silencing TGF-β pathway | In vitro | [20] |
| miR-326 | High | Th17 differentiation through ets-1 | In vivo | [30] |
| miR-199a | Low (PBMCs) | KRS (MAPK/JAK-STAT) | Systemic analysis | [49] |
| miR-142-3p | High (PBMCs) | IL7R and KRS (MAPK/JAK-STAT) | Systemic analysis | [49] |
| miR-328-3p | High | RAC2 (low in MS) | Systemic analysis | [50] |
| miR-20a-5p | High | EIF4EBP2 (low in MS) | Systemic analysis | [50] |
| miR-let-7g | Low | TLR4 and HTATIP2/TIP30 (high in chronic lesions) | Bioinformatics | [51] |
| miR-150 | Low | SOCS1, SPI1 and EPHB2 | Bioinformatics | [51] |
| miR-let-7i | High (serum exosomes) | Inhibit Treg induction via IGF1R and TGFβRI signaling in CD4+ T cells hence Treg differentiation | In vitro | [45] |
| miR-27-b, miR-128, miR-141, miR-500a, miR-let-7a, miR-let-7b | High (white matter of MS patients and spinal cord of EAE) | Targets SOCS1 and TGFβRI | In vitro and In vivo | [42] |
| miR-21-5p, miR-26b-5p, miR-29b-3p, miR-142-3p and miR-155-5p | Low (CD4+ T cells of SPMS patients) | SOCS6/ regulation of T cell activation | In vitro | [52] |
| miR-23a | High | Th17 differentiation NIK and PIAS3 expressions | In vitro and In vivo | [110] |
| miR-200a | Low (spinal cord of EAE) | Targets IL-6/IL-23-STAT3 pathway (PIAS3 is an inhibitor of STAT3) Induce inflammatory | In vitro and In vivo | [33] |
| miR-183c | High | High (spinal cord of EAE) | In vitro and In vivo | [33] |
| miR-106b | High | Th17 differentiation through downregulation and hypermethylation of STAT1 Targets Smad7, Smad2/3 and IL-2 secretion | In vivo | [90] |
| miR-92a | High | High (reactive astrocytes) | Systemic analysis | [32] |
| miR-182 | High | Leukocyte migration through targeting CCL7 Modulates Foxp3 and Treg cell differentiation | In vitro and In vivo | [111] |
| miR-590 | High | Th17 differentiation via targeting tobi of the tob/bgl family; CXC13, CD92, and IL-23R | In vitro | [112] |
| miR-448 | High | PTPN2 protein; triggering Th17 response | In vitro | [113] |
| miR-27a | High | Targets negative regulators of Th17 cell differentiation Inhibit Th17 differentiation through targeting OGT | In vitro and In vivo | [116] |
| miR-132 | Low (CD4+ T cells) | The anti-inflammatory effect through inhibiting proinflammatory cytokine production | In vivo | [117] |
| miR-214 | Low | Inhibits Th17 differentiation | In vivo | [115] |
| miR-146a | Low | Inhibits IL-6 and IL-21; hence Th17 differentiation | In vitro and In vivo | [118] |
| miR-26a | Low | Targets IL-6, Foxp3 hence enhancing Treg and reducing Th17 differentiation | In vitro and In vivo | [102] |
| miR-181c | High | Targets STAT3 In vitro and in vivo | [94] |
| miR-141 | High | Enhance Th1/Th17 modulation/Low | In vitro and in vivo | [94] |
| miR-26a | Low (CD4+ T cells) | Targets STAT3 | In vitro and in vivo | [90] |
| miR-182 | High | Inhibits Th17 differentiation through targeting OGT | In vitro and In vivo | [111] |
| miR-27a | High | Targets negative regulators of Th17 cell differentiation Inhibit Th17 differentiation through targeting OGT | In vitro and In vivo | [116] |
| miR-132 | Low (CD4+ T cells) | The anti-inflammatory effect through inhibiting proinflammatory cytokine production | In vivo | [117] |
| miR-214 | Low | Inhibits Th17 differentiation | In vivo | [115] |
| miR-146a | Low | Inhibits IL-6 and IL-21; hence Th17 differentiation | In vitro and In vivo | [118] |
| miR-26a | Low | Targets IL-6, Foxp3 hence enhancing Treg and reducing Th17 differentiation | In vitro and In vivo | [102] |
| miR-181c | High | Targets STAT3 | In vitro and in vivo | [94] |
| miR-141 | High | Enhance Th1/Th17 modulation/Low | In vitro and in vivo | [94] |
| miR-26a | Low (CD4+ T cells) | Targets STAT3 | In vitro and in vivo | [90] |
| miR-182 | High | Inhibits Th17 differentiation through targeting OGT | In vitro and In vivo | [111] |
| miR-27a | High | Targets negative regulators of Th17 cell differentiation Inhibit Th17 differentiation through targeting OGT | In vitro and In vivo | [116] |
5. Long non-coding RNAs

LncRNAs are non-coding RNAs ranging in length from 200 nts to 100 kilobases (kb) lacking specific open reading frames. RNA polymerase II transcribes them, and their expression levels are usually tissue-specific and lower than protein-coding genes. Surprisingly, recent studies showed that some lncRNAs have open reading frames, which could direct towards a translational ability to encode proteins [55, 56]. LncRNAs have been associated with epigenetics, alternative splicing, nuclear import, serve as structural components, as precursors to small RNAs, and even regulators of mRNA decay [57].

### 5.1. EAE

LncRNA labeled 1700040D17Rik was found to be downregulated in EAE models, and studies revealed its function to be associated with Th17 cells differentiation through the regulation of RORγt, a key transcription factor [58]. MALAT1 was investigated in EAE mice, and its expression was reduced in the spinal cords, activated splenocytes, and lesions of MS patients and OPCs from EAE [59].

### 5.2. Circulating exRNAs

#### 5.2.1. Serum/plasma of MS patients

Studies on serum samples of MS patients reported increased expression in MALAT1 and Inc-DC lncRNA in RRMS and SPMS patients compared to controls, with SPMS patients showing higher differences to controls [62]. Another study reported upregulation in NEAT1, TUG1, and RN7SK RNA in RRMS patients [63], in TUG1 in SPMS patients, in long intergenic non-protein coding RNA 293 (LINC00293) and RP11-29G8.3 in PPMS patients, and downregulation in non-protein RNA in RRMS patients [63].

#### 5.2.2. Peripheral blood of MS patients

Looking into the role of lncRNAs in different immune cells, lncRNA DDI74 was found to be upregulated in PBMCs of MS patients compared to healthy controls with a 4.32-fold increase. Further experiments on naïve CD4+ T cells proved that lncRNA DDI74 regulates Th17 cell differentiation through targeting DDIT4 and the mTOR pathway [66]. Growth arrest-specific transcript (GASS) was an epigenetic regulator of TUG1 expression negatively correlates with miR-9-5p, positively with NF-kB/p50, and it was verified that TUG1 negatively regulates miR-9-5p; hence NF-kB/p50 is affected as a direct target of miR-9-5p [60]. Gm15575 is a proinflammatory lncRNA regulating Th17 function through acting as a competing endogenous RNA for miR-686 and positively regulating CCL7 in TH17 differentiation in EAE [61].

### Table 1 (continued)

| miRNA    | Expression       | Pathway                                      | Experiment       | Reference |
|----------|------------------|----------------------------------------------|------------------|-----------|
| miR-27a  | High             | Inhibits remyelination, OPCs proliferation, and dysregulates Wnt-B catenin pathway | In vivo, in vitro | [40]      |
| Let-7    | Low              | Targets Bl1, I22r, Ccr2 and Ccr5            | in vivo          | [123]     |
| miR-384  | High             | Targets IL17                                 | in vivo          | [124]     |
| miR-140-5p| Low (CD4+ T cells)| Targets mitochondrial respiratory pathways and DNA methylation | in vivo          | [34]      |
| miR-125a-3p| High (active lesions of MS patients and OPCs from EAE)| Targets and inhibits remyelination | in vivo          | [39]      |

### Table 2

| miRNA      | Expression       | Reference |
|------------|------------------|-----------|
| miR-155 and miR-301a | Low (serum)     | [106]     |
| miR-326    | High             | [106]     |
| miR-150    | High (CSF)       | [105]     |
| miR-22-3p, miR-660-5p | High (serum exosomes of interferon treated patients) | [126] |
| miR-486-5p, miR-451a, miR-let-7b-5p, miR-320b and miR-122-5p, miR-122-5p, miR-196-5p, miR-301a-5p and miR-531-5p | Low (serum exosomes of interferon treated patients) | [126] |
| miR-320a, miR-125a-5p, miR-652-3p, miR-185-5p, miR-942-5p and miR-25-3p | High (PBMCs) | [100] |
| miR-181c   | High (CSF and serum) | [127] |
| miR-572    | High (during relapses and SPMS patients) | [128] |
| miR-191-5p and miR-24-3p | Low (serum) | [129] |
| miR-219    | Low (CSF)        | [130]     |
| miR-20a-5p | Low              | [99]      |
| miR-20a    | High (PBMCs)     | [101]     |
| miR-96     | Higher (PBMCs of patients in remission (disease quiescence) | [131] |
| miR-497, miR-30a-5p and miR-149, miR-300, miR-450b-5p, miR-128-3p | Low (serum) | [46] |
| miR-125a-5p| Low (serum)      | [47]      |
| miR-145a   | High (serum)     | [48]      |
| miR-124a, miR-223, miR-125a, miR-30c, miR-23a and miR-181a | High (monocytes) | [54] |
| miR-124 and miR-155 | Low (serum) | [54] |
| miR-21 and miR-146a/b, miR-181 and miR-663 | High (CSF) | [43] |
| miR-106a   | Low (Peripheral blood) | [133] |

A list of the differentially expressed miRNAs in MS patients states the area of significance and the study’s reference to being useful as disease biomarkers.
microglial polarization by suppressing microglial M2 polarization. This may be done through GAS5 suppression of transcription of TRF4 by recruiting the polycomb repressive complex 2 (PRC2) and inhibiting M2 polarization [67]. Linc-MAF4 was found upregulated in PBMCs of MS patients and participates in the pathogenesis of MS with its main activities in regulating Th1/Th2 differentiation by inhibiting MAF, a Th2 cell transcription factor [68–70]. A recent study showed a consistent upregulation in MALAT1 in MS patients with its overexpression/knockdown experiments showing modulation in endogenous expression of splicing factors and alternative splicing of MS-associated genes possibly contributing to its pathogenesis [71].

Several studies reported expression levels of lncRNAs in peripheral blood for their use as promising biomarkers of the disease; NEAT1, TUG1, PANDA [72], THRIL [73], Inc-DC [74], APO1-AS, IFNG-AS1 [75], PINK1-AS [76], GAS8 and GAS8-AS1 [77] were upregulated in RRMS patients. In contrast, lincR-Gng2-5-AS [78] was upregulated in both RRMS and SPMS patients correlating to disease severity (EDSS) and showing excellent diagnostic power. NEAT1 expression was inversely correlated with age at onset and disease duration in female patients, while TUG1 was inversely correlated with disease duration in females [72]. LincR-Epas1-3′ AS was downregulated in peripheral blood of RRMS, and SPMS patients [78], PVT1, FAS-AS1 [73], Inc-MK167IP, HNF1A-AS, LINC00305 [79], NR_003531.3 [80], SPRY-IT1, HOXA-AS2, LINC-ROR, and MEG3 [81] were significantly downregulated in peripheral blood of MS patients compared to controls with high diagnostic power. Tables 3 and 4 summarize lncRNAs in MS used as biomarkers and their target proteins or pathways.

6. Circular RNAs

Recently, another family of non-coding RNAs, circular RNAs, has emerged as a new player in the complex network of gene-expression

Table 3

| LncRNA   | Expression | Pathway                                      | Experiment | Reference |
|----------|------------|----------------------------------------------|------------|-----------|
| 1700040D1Rik | Low        | Th17 differentiation (RORϒT)                 | In vitro and In vivo | [58]       |
| DDI4     | High (PBMCs)| mTOR                                          | Ex vivo    |           |
| GAS5     | High (microglia)| Inhibit M2 polarization                      | In vitro and In vivo | [66]       |
| Gm15575  | High        | Regulates CCL7 and Th17 differentiation       | In vivo    |           |
| Linc-MAF4 | High (PBMCs)| Inhibit MAF                                    | In vivo    | [69]       |
| MALAT1   | Low (Spinal cord, activated splenocytes, and macrophages) | Increase in Th1/Th17 profile and decrease in Tregs and high M1 polarization | In vivo | [59,62]    |
| PVT1     | Low (EAE)  | Sponge miR-21-5p, increase SOCS3, Treg cells, decrease JAKs/STAT3 pathway and Th17 cells regulate miR-9-5p and NF-kB1/p50 | In vivo | [96]       |
| TUG1     | High        | Regulates miR-9-5p and NF-kB1/p50             | In vivo    | [60,63,72] |
regulation. They have the unique ability to inhibit miRNAs by blocking their activity and acting as sponges, and neutralizing them [82]. This regulating role and high stability in biofluids make them seemingly good candidates as biomarkers. They are classified according to their origin or relationship to adjacent coding RNAs and hence appear to be a complex group of transcripts of crucial biological roles [83].

6.1. Circulating exRNAs

Cardamone et al. identified over 400 differentially expressed circRNAs in PBMCs of RRMS patients compared to healthy controls, and in particular, circ_016693 showed 2.8-fold upregulation in RRMS, which was generated by the alternative splicing abnormality of the Gasdermin B gene [84]. Expression profile of circRNAs comparing peripheral blood leukocytes of MS patients and controls revealed the downregulation of circ_0005402 and circ_0035560 inside ANXA2 gene in patients suggesting its use as biomarkers [83]. Moreover, Paraboschi et al. reported upregulated expression of circ_0043813, derived from Lnc-MKI67IP, HNF1A-AS and Lnc-DC High (Peripheral blood) [79]. TUG1 and miR-9-5p was concluded as they have a correlation to being useful as disease biomarkers.

Table 4

| LncRNA Expression Reference |
|-----------------------------|
| AC007182.6: Low (PBMCs) [134] |
| AC007278.2: High (CD4+ T cells) [135] |
| AC009948.5: Low (PBMCs) [134] |
| AK080435: Low [136] |
| AL450999.2: Low (PBMCs) [134] |
| AL129874.12: Low (PBMCs) [137] |
| APOA1-AS and IFN-AS1 High (Peripheral blood) [75] |
| CPSF7: High (PBMCs) [136] |
| GSTF2: Low (PBMCs) [138] |
| FAS-AS1: Low (PBMCs) [72] |
| GAS5: High (serum) [65] |
| GAS8-AS1: High (Peripheral blood) [77] |
| Gm140005: High (brain tissues and activated astrocytes) [136] |
| Gm12478: High (brain tissues and activated astrocytes) [136] |
| GSTT1-AS1: Low (PBMCs) [139] |
| HULC: High [140] |
| HU1: High (PBMCs) [136] |
| JN9-AS1: Low (PBMCs/high) [135, 139] |
| Lin-0262: High (Peripheral blood) [78] |
| Lin-918:1-3′AS Low (Peripheral blood) [80] |
| linncRNA9608: Low [136] |
| linncRNA117: Low [136] |
| Lnc-DC: High (Peripheral blood) [62, 74] |
| Lnc-MK676P, HNF1A-AS and LINC03035: Low (Peripheral blood) [79] |
| NEAT1: High (Peripheral blood) [62, 72] |
| NRI_003531.3: Low (Peripheral blood) [80] |
| PANDA: High (Peripheral blood) [72] |
| PINK1-AS: High (Peripheral blood) [76] |
| PTEN: Low (PBMCs) [73] |
| RN7SK: High [61] |
| RP11-12606.1: High (PBMCs) [134] |
| RP11-530C5.1: High (PBMCs) [137] |
| RP11-980D18.3: Low (Peripheral blood) [134] |
| SPRY1-T1, HOXA-AS1, LINC-ROR and MEG3: Low (Peripheral Blood) [61] |
| THREIL: High (PBMCs) [71] |
| TUG1, LINF00293 and RP11-29G8.3: High (PBMCs) [64] |
| LINC751-AS1: Low (Serum) [64] |

7. Cross-over between regulation of IncRNAs and miRNAs in MS

A correlation between TUG1 and miR-9-5p was concluded as they were negatively correlated and resulted in a consequent effect on NF-kB1/p50 that is a direct target of miR-9-5p [60]. It is interesting to highlight a pathway regulated by various miRNAs in the setting of MS disease. MiR-let-7i inhibited TGFBR1, miR-181c decreased TGFβ signaling, and miR-21 regulated it through SMAD7, a negative regulator of TGFβ [45, 89, 90]. Moreover, an in-silico analysis showed that TGFβ could be a target for miR-141 and miR-200a [91]. Another analysis of miRNAs in PBMCs from MS patients concluded that the up-regulation of miR-27b, miR-128, miR-141, miR-500a, miR-let7a, and b could be correlated to the disrupted signaling of TGFβ [92]. Another protein noticed with multiple miRNAs interactions in MS is the STAT3 transcription factor. It is inhibited by miR-let-7i-5p, miR-20b, and regulated indirectly by miR-301a through its action on PIAS3, which inhibits STAT3 [93–95]. Some IncRNAs act as competing endogenous RNAs for miRNAs such as Gm15575 and GASS for miR-686 and miR-137, respectively [61, 65]. Along with its effect on miR-686, Gm15575 positively regulates CCL7 enhancing Th17 differentiation in EAE while miR-23b was found to suppress CCL7 inhibiting the migration of pathogenic T cells in EAE development [32, 61]. An interesting correlation is the role of PV1T1 IncRNA in regulating Th17 cell response in EAE by sponging miR-21-5p, upregulating SOCS5, and inactivating the JAKs/STAT3 pathway providing a potential therapeutic pathway [96]. These observations open the door to new investigations studying which ncRNA would have the upper hand in regulating those pathways influencing MS pathogenesis.

8. Possible factors affecting expressions of ncRNAs

8.1. MALAT1

From reviewing the IncRNAs in MS disease, some IncRNAs have the potential to be used as biomarkers such as Inc-MAF4, Inc-DC, NEAT1, TUG1, PANDA, RN7SK, and MALAT1. However, studies on MALAT1 showed discrepancies as an investigation on EAE mice showed decreased expression of MALAT1 in spinal cords, activated splenocytes, and macrophages, while the study investigating human serum showed increased expression of MALAT1 [59, 62, 71]. The differences could be due to the differences between the mouse model and the actual disease in humans or due to distinct mechanisms in immune cell content and biomarkers for MS [86]. Another group analyzing circRNAs in PBMCs of MS patients and healthy controls showed the downregulation of circ_000478 and circ_0116639 in patients compared to controls suggesting their use as biomarkers [87]. Another recent paper shed light on the mechanistic role of circNPP4B in promoting TH17 differentiation and progression of EAE through targeting miR-30a, suggesting a potential therapeutic target of Th17 mediated MS [88]. Table 5 summarizes circRNAs in MS and their differential expression for use as biomarkers.

Table 5

| CircRNA Expression Reference |
|-----------------------------|
| Circ_016693: High (PBMCs) [84] |
| Circ_0005402, circ_0035560: Low (PBMCs) [83] |
| Circ_0043813: High (PBMCs) [85] |
| PAD4, ABCA13, AFF2, NEIL3, AGFG1 and ATP8B4: High (PBMCs) [86] |
| Circ_000478, circ_0116639: Low (PBMCs) [87] |
| CircNPP4B: High [88] |
their secretory ability of ncRNAs. This is confirmed by other studies on SLE and RA patients showing increased expression of MALAT1 in circulation [97,98].

8.2. miR-17-92 cluster

Moreover, while reviewing the role of miRNAs in MS, a contradiction was found regarding the role of miR-17 in MS as the study by Cox et al. showed decreased expression of miR-17 in the peripheral blood of MS patients while the study by Lindberg et al. reported increased expression in CD4+ T cells of MS patients. This could be the result of differences in methodology as Cox et al. used PAXgene RNA tubes that stabilize RNA on collection and include a high portion of neutrophil RNA due to the whole blood collection, while Lindberg study used RNeasy mini kit on isolated CD4+ T cells and the resultant RNA could be very labile during the time needed to purify miRNA. Also, the pool of patients used differs as Lindberg et al. had 23 RRMS patients against 20 controls while Cox et al. performed the study on 59 MS patients of all subtypes and 37 controls [22,26]. miR-20a was also discussed in the study by Cox et al. and reported to be downregulated in MS patients, while the study by Yang et al. reported upregulated tendency of miR-20a-5p in MS patients compared to control. However, this was concluded from a qPCR experiment on whole blood samples from 3 patients vs. 3 controls and contradicted their results from microarray analysis that pointed to the downregulation of miR-20a in MS patients; hence the probability of low miR-20a expression is more robust [22,50]. Moreover, Keller et al. confirmed the downregulation of miR-20a-5p in whole blood samples of RRMS/CIS patients compared to healthy controls [99]. Since miR-20a is part of the miR-17-92 cluster, it suggests that the expression of miR-17 follows the same pattern as miR-20a and is under-expressed in MS patients.

8.3. miR-125a

miR-125a-5p showed a compelling contradictory expression in brain capillaries of MS as opposed to PBMCs or active lesions from MS patients. A study by Reijerkerk et al. showed decreased expression of miR-125a-5p in brain capillaries from post-mortem MS patients’ samples vs. controls. Upon in vitro studies using brain endothelial cell lines, knockdown of miR-125a-5p reduced the barrier-enhancing effect of astrocytes and altered expression of VE-cadherin. Previous findings, endothelin-1 expression in vascular endothelial cells. Important to mention, this study was performed using a total of 4 specimens, 2 PPMS and 2 SPMS patients vs. controls [41]. However, numerous studies confirm the upregulation of miR-125a, both -3p or -5p, in PBMCs [49], monocytes [54], active lesions of MS patients [39] and EAE [37,39]. Moreover, another study by Nuzziello et al. showed upregulated expression of miR-125a-5p in PBMCs of MS patients not specifying subtypes but untreated compared to controls. The study employed 40 patients and 40 controls, making the results robust [100]. Hence, the upregulation of miR-125a seems to be a more robust conclusion.

8.4. miR-26a

A study on 40 MS Egyptian patients and 20 controls reported increased expression of miR-26a in whole blood samples of patients compared to control [101]. However, a previous study examined the expression of miR-26a in PBMCs of RRMS patients and concluded an under-expression in all MS patients [102]. The difference in results could be due to a limited number of clinical subjects, differences in disease stages of subjects, the heterogeneity in the miR26 family members, or the genetic polymorphism between the different subjects’ nationalities.

8.5. miR-150

miR-150 has shown differences in expression between CSF, serum, and PBMCs of MS patients. A study investigating the potential of miR-150 to act as a biomarker in CSF fluids showed increased expression of miR-150 in cell-free CSF samples of MS patients compared to controls correlating with immunologic parameters and inflammatory properties. However, treatment of those patients with Natalizumab caused reduced miR-150 expression in CSF but a surprising increase in plasma expression. This could be explained by the suggestion that miR-150 is released by immune cells, and these differences are owed to drug-induced changes in immune cell numbers in both compartments, CSF and plasma [103]. Moreover, a previous study by Martirelli-Boneschi concluded reduced expression of miR-150 in PBMCs of MS patients, suggesting that miR-150 is actively stored in immune cells and its export has a significant role in disease pathogenesis [51]. However, further studies with larger cohorts need to be done to conclude the potential diagnostic and prognostic use of miR-150 in biological fluids.

8.6. miR-142 and miR-21

miR-142-3p was reported downregulated in isolated CD4+ T cells from SPMS patients while found upregulated in another study investigating miR-142-3p in PBMCs of RRMS and its relation with the function of T regulatory cells [49,52]. This difference could be owed to the nature of the secondary progressive disease compared to the RRMS and the higher average disease duration between the two cohorts. A similar difference was seen in the expression of miR-21 in CD4+ T cells of SPMS patients, where it was reported downregulated while overexpression of miR-21 was reported in Th17 differentiating cells of RRMS patients [52,90]. However, a small amount of miR-21 was found in other subsets of T cells in RRMS patients, suggesting that samples are PBMCs or total CD4+ T cells could yield results different from those concluded from single subsets of T cells.

8.7. miR-301a

We came across two studies discussing the upregulation of miR-301a in CD4+ T cells from MS patients or EAE models and how it contributes to Th17 differentiation [95,104]. However, another study by Selmaj et al. reported the decreased expression of exosomal miR-301a in RRMS patients, especially patients encountering relapses [105]. This could be owed to miR-301a export and secretion in exosomes is decreased in patients with RRMS, and miR-301a stays in the immune cells to perform its functions. Moreover, another study evaluated the serum expression of miR-301 in RRMS patients and reported under expression, which increases relatively during the post-acute phase than during the stable phase of remission [106]. The expression differs depending on the inflammatory stage could be the reason for the discrepancies in the in vitro or in vivo experiments, mainly evaluating biomarkers around or just after induction of disease or inflammation.

8.8. miR-155

An interesting case is seen with miR-155 as it is reported under-expressed in serum of RRMS patients with lower expression in stable patients than post-acute patients [106] and monocytes of RRMS and PPMS patients compared to controls [54]. On the contrary, another study reported miR-155 overexpressed in serum samples of MS patients [46] and inactive lesions of RRMS patients compared to the inactive lesion and normal controls. This could suggest that miR-155 plays a role in the inflammatory process of the disease; hence is increased during an active inflammatory phase or relapse phase and decrease during the stable phase [28]. Moreover, the decreased serum levels could be explained by the process of miR-155 secretion by immune cells is an active process that is dysregulated in RRMS patients. Additionally, a
difference in the time of sample withdrawal from the last relapse or last therapeutic dose could yield such a difference in conclusions. On a side note, miR-155 was reported under-expressed in CD4+ T cells of SPMS patients, and as mentioned previously, this could be due to the difference in nature of the two disease subtypes where the RRMS is more prone to the inflammatory profile than the SPMS and the apparent difference of duration of disease [52].

9. Limitations of miRNA/IncRNA as biomarkers/therapeutics for MS

The main issue in dealing with MS is that the disease is heterogeneous and for the diagnosis to be confirmed, a patient might have been experiencing the disease for several years. Also, the treatments do not necessarily work well with all patients, and there is no specific disease biomarker to reflect the prognosis following a particular treatment; hence a period of at least 6 months to a year needs to be given to consider a treatment ineffective. This is a lot of lost time for the patient with a demyelinating disease; however, with the current advances in understanding the pathogenesis of the disease and looking into the molecular and genetic contributions, a more focused approach in developing new therapies can be implemented with a brighter outlook for future therapies.

Some of the research limitations that appear in the MS field are that the EAE mouse model and other murine models will always show differences compared to the human disease; hence, the conclusions brought about from EAE studies will need to be verified somehow to show effectiveness in humans. A new direction of studies is emerging where scientists focus on biomarkers of therapeutic response to shorten the period of therapy trial where patients usually have to wait for at least 6 months to decide if the therapy is effective. In light of this, several studies are investigating serum, plasma, and blood expression of miRNAs in responders and non-responders of therapeutic agents [107–109]. Moving forward with this, the field requires several studies to have enough evidence for using specific ncRNAs as prognostic biomarkers of therapeutic efficacy. A patient is tested for that biomarker and can assume with particular specificity whether he will respond to a specific therapeutic efficacy. A patient is tested for that biomarker and can assume with particular specificity whether he will respond to a specific therapeutic treatment or not.

This review worked on summarizing, evaluating, and concluding the roles of regulatory miRNAs and IncRNAs in MS pathogenesis. This shed light on a promising axis of molecular pathways that needs further investigation into how they contribute to MS pathogenesis and target them therapeutically. Moreover, the review pointed out certain overlaps between miRNA and IncRNA regulations for interesting studies reviewing which one has the upper hand in regulating such a pathway, which will be better as a therapeutic target. Nevertheless, due to disease heterogeneity, contradictions in the field have been spotted, and probably reasons were suggested for future references and discussions. Altogether, miRNAs and IncRNAs possess a crucial role in regulating disease pathogenesis, and understanding their interactions would aid in better targeting them therapeutically.

Funding
Not Applicable.

Availability of data and material
Not Applicable.

Code availability
Not Applicable.

Authors’ contributions
Elkhodiry, A. contributed to literature reviewing, manuscript writing, and editing; El Tayebi, H.M. contributed to the designation, revision, and correction of the manuscript.

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References
[1] L.G. Dimitrov, B. Turner, What’s new in multiple sclerosis? Br. J. Gen. Pract. 64 (6291) (2014) 612–613.
[2] M.T. Wallin, et al., Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol. 18 (3) (2019) 269–285.
[3] C. O’Gorman, R. Lucas, B. Taylor, Environmental risk factors for multiple sclerosis: a review with a focus on molecular mechanisms, Int. J. Mol. Sci. 13 (9) (2012) 11718–11752.
[4] F.D. Lublin, S.C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis, Neurology 46 (4) (1996) 907–911.
[5] F.D. Lublin, et al., Defining the clinical course of multiple sclerosis, The 2013 revisions E3 (3) (2014) 278–286.
[6] C.S. Constantinescu, et al., Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS), Br. J. Pharmacol. 164 (4) (2011) 1079–1106.
[7] A.P. Robinson, et al., The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment, Handb. Clin. Neurosci. 122 (2014) 173–189.
[8] I. Lazibat, M. Rubnic Majdak, S. Zupanic, Multiple sclerosis: new aspects of immunopathogenesis, Acta Clin. Croat. 57 (2) (2018) 352–361.
[9] C.M. Poser, Pathogenesis of multiple sclerosis. A critical reappraisal, Acta Neuropathol. 71 (1–2) (1986) 1–10.
[10] J.S. Mattick, I.V. Makunin, Non-coding RNA, Hum. Mol. Genet. 15 (suppl_1) (2006) R17–R29.
[11] S. Dahariya, et al., Long non-coding RNA: classification, biogenesis and functions in blood cells, Mol. Immunol. 112 (2019) 82–92.
[12] M.P. Perron, P. Provent, Protein interactions and complexes in human microRNA biogenesis and function, Front. Biosci. 13 (2008) 2537–2547.
[13] N. Rajewsky, L’On’yx miRNA targets? Nat. Struct. Mol. Biol. 13 (9) (2006) 754–755.
[14] C. Easa, et al., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting, Cell Metabol. 3 (2) (2006) 87–98.
[15] D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function, Cell 116 (2) (2004) 281–297.
[16] L.A. Macfarlane, P.R. Murphy, MicroRNA: biogenesis, function and role in cancer, Curr. Genom. 11 (7) (2010) 537–561.
[17] V. Ambros, et al., A uniform system for microRNA annotation, RNA 9 (3) (2003) 277–279.
[18] T. Gura, A silence that speaks volumes, Nature 404 (6780) (2000) 804–808.
[19] H. Kim, J.S. Kim, A guide to genome engineering with programmable nucleases, Nat. Rev. Genet. 15 (5) (2014) 321–334.
[20] L.J. Scherer, J.J. Rossi, Approaches for the sequence-specific knockdown of miRNA, Nat. Biotechnol. 21 (12) (2003) 1457–1465.
[21] D. Otaegui, et al., Differential micro RNA expression in PBMC from multiple sclerosis patients, PLoS One 4 (7) (2009), e6309.
[22] M.B. Cox, et al., MicroRNAs miR-17 and miR-20a inhibit T cell activation genes and are under-expressed in MS whole blood, PLoS One 5 (8) (2010), e12132.
[23] A. Keller, et al., Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls, PLoS One 4 (10) (2009), e7440.
[24] R. Gandhi, et al., Circulating microRNAs as biomarkers for disease staging in multiple sclerosis, Ann. Neurol. 73 (6) (2013) 729–740.
[25] J.J. Li, et al., Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression, PLoS One 9 (3) (2014), e90770.
[26] R.L. Lindberg, et al., Altered expression of miR-17-5p in CD4+ lymphocytes of reflecting-remitting multiple sclerosis patients, Eur. J. Immunol. 40 (3) (2010) 888–898.
[27] S.Q. Liu, et al., miR-17-92 cluster targets phosphatase and tensin homology and Ikaros Family Zinc Fingers 4 to promote TH17-mediated inflammation, J. Biol. Chem. 289 (18) (2014) 12446–12456.
[28] A. Junker, et al., MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47, Brain 132 (Pt 12) (2009) 3342–3352.
[29] G. De Santis, et al., Altered microRNA expression in T regulatory cells in course of multiple sclerosis, J. Neuroimmunol. 226 (1–2) (2010) 165–171.
[30] C. Du, et al., MicroRNA miR-326 regulates TH17 differentiation and is associated with the pathogenesis of multiple sclerosis, Nat. Immunol. 10 (12) (2009) 1252–1259.
A.A. Elkhodiry and H.M. El Tayeb

Non-coding RNA Research 6 (2021) 187–199

198

[31] M. Thamilarasan, et al., MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis, Autoimmun. Rev. 11 (3) (2012) 174–179.

[32] Y. Zhang, et al., miR-23b suppresses leukocyte migration and pathogenesis of experimental autoimmune encephalomyelitis by targeting CCL7, Mol. Thera. 26 (2) (2018) 582–592.

[33] X. Liu, et al., MicroRNA-409-3p and MiR-1896 co-operatively participate in IL-17 induced inflammation through sponging miR-686 in Th17 cells, Mol. Immunol. 125 (2020) 32–38.

[34] S. Zhu, et al., miR-140-5p regulates T cell differentiation and attenuates inflammation in cell proliferation in rats, J. Cell. Biochem. 121 (11) (2020) 4347–4363.

[35] H.C. Long, et al., MiR-125a-5p regulates vitamin D receptor expression in a mouse model of experimental autoimmune encephalomyelitis, Neurosci Bull 36 (2) (2020) 110–120.

[36] C.P. Duffy, C.E. McCoy, The role of MicroRNAs in repair processes in multiple sclerosis, Cells 9 (7) (2020) 1711.

[37] M. Thamilarasan, et al., Circular RNAs as a novel layer of biomarkers in multiple sclerosis, Aging (Albany NY) 11 (13) (2019) 4463–4481.

[38] A. Safa, et al., Downregulation of cancer-associated lncRNAs in peripheral blood of multiple sclerosis patients, J. Mol. Neurosci. 70 (10) (2020) 1533–1540.

[39] A. Safa, et al., Expression analysis of lncRNA GAS-DC as a new biomarker for multiple sclerosis, J. Mol. Neurosci. 70 (7) (2020) 1711.

[40] M. Patoughi, et al., GAS8 and its naturally occurring antisense RNA as biomarkers in multiple sclerosis, Immunobiology 224 (4) (2019) 560–564.

[41] T. Tambari, et al., Expression analysis of long non-coding RNA Inc-DC in HLA-DRB1*15:01-negative patients with multiple sclerosis: a probable cause for gender differences in multiple sclerosis susceptibility? J. Mol. Neurosci. 71 (2020) 32–40.

[42] C.F. Talebi, et al., MicroRNA-142 regulates inflammation and T cell differentiation and the pathogenesis of EAE, Front. Immunol. 9 (2018) 582.

[43] M. Patoughi, et al., Evaluation of the expression levels of three long non-coding RNAs in multiple sclerosis patients, Curr. Med. Chem. 26 (18) (2017) 3564–3572.

[44] G. Cardamone, et al., The characterization of GSDMB splicing and backsplicing profiles identifies novel isoforms and a circular RNA that are dysregulated in multiple sclerosis, Int. J. Mol. Sci. 18 (3) (2017) 521.

[45] E.M. Paraboschi, et al., Interpreting non-coding genetic variation in multiple sclerosis, Aging (Albany NY) 11 (1) (2019) 17–18.

[46] M. Patoughi, et al., Evaluation of the expression levels of long non-coding RNAs in multiple sclerosis patients, Curr. Med. Chem. 26 (18) (2017) 3564–3572.

[47] J. Bazin, et al., Global Analysis of Ribosome-Associated Noncoding RNAs Unveils a Novel mRNA Regulatory Network, Nat. Commun. 9 (1) (2018) 17–18.

[48] A. Amoruso, et al., Innate and central nervous system-related miRNAs expression profiling in monocytes of multiple sclerosis patients, Sci. Rep. 10 (1) (2020) 6125.

[49] J. Bazin, et al., Global Analysis of Ribosome-Associated Noncoding RNAs Unveils New Modes of Translational Regulation, vol. 114, pp. E10018–E10027, 46.

[50] H. Wang, et al., Global and cell-type specific properties of lncRNAs with ribosome occupancy, Nucleic Acids Res. 45 (5) (2017) 2786–2796.

[51] E.A. Gibb, C.J. Brown, W.L. Lam, The functional role of long non-coding RNA in human carcinomas, Mol. Cancer 10 (1) (2011) 38.

[52] W. Guo, et al., Identification of IncRNA 17-684 and 17-685 as biomarkers with the pathogenesis of multiple sclerosis by targeting RORgammat and MAF, FASEB J. 31 (2) (2017) 519–525.

[53] Z. Bian, et al., Gm15575 functions as a ceRNA to upregulate CCL7 expression through sponging miR-686 in Th17 cells, Mol. Immunol. 125 (2020) 32–42.

[54] O.G. Shaker, et al., LncRNAs, MALAT1 and lnc-DC as potential biomarkers for the pathogenesis of EAE mice via targeting SOCS3/STAT3 signaling, Glia 67 (1) (2019) 101–112.

[55] J. X. Li, et al., CircRNAs on guard, Int. Immunopharm. 65 (2018) 60–63.
R. Liu, et al., MicroRNA-15b suppresses Th17 differentiation and is associated with pathogenesis of multiple sclerosis by targeting O-GlcNAc transferase, J. Immunol. 198 (7) (2017) 2626–2639.

H. Hanieh, A. Alzahrani, MicroRNA-132 suppresses autoimmune encephalomyelitis by inducing cholesterin anti-inflammation: a new Ahe-based exploration, Eur. J. Immunol. 43 (10) (2013) 2771–2782.

B. Li, et al., miR-146a modulates autoactive Th17 cell differentiation and regulates organ-specific autoimmunity, J. Clin. Invest. 127 (10) (2017) 3702–3716.

C. Cerutti, et al., MiR-126 and miR-1267 regulate shear-resistant firm leukocyte adhesion to human brain endothelium, Sci. Rep. 7 (2017), 45284.

X. Qu, et al., MiR-30a inhibits Th17 differentiation and demyelination of EAE mice by targeting the IL-21R, Brain Behav. Immun. 57 (2016) 193–195.

X. Qu, et al., MiR-384 regulates the Th17/Treg ratio during experimental autoimmune encephalomyelitis pathogenesis, Front. Cell. Neurosci. 11 (2017) 88.

K. Ichiyama, et al., The MicroRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression, Immunity 44 (6) (2016) 1284–1296.

C.C. Angelou, et al., Differentiation of pathogenic Th17 cells is negatively regulated by let-7 MicroRNAs in a mouse model of multiple sclerosis, Front. Immunol. 10 (2019) 3125.

J. Han, et al., STAT3 regulates miR-384 transcription during Th17 polarization, Front Cell Dev Biol 7 (2019) 253.

C. Wan, et al., MicroRNA 182 promotes T helper 1 cell by repressing hypoxia induced factor 1 alpha in experimental autoimmune encephalomyelitis, Eur. J. Immunol. 49 (12) (2019) 2184–2194.

I. Manna, et al., Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients, Faseb. J. 32 (8) (2018) 4241–4246.

J. Ahlbrecht, et al., Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis, Mult. Scler. 22 (9) (2016) 1202–1214.

R. Mancuso, et al., MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression, J. Transl. Med. 13 (2015) 148.

J. Vistbakka, et al., Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients, Acta Neurol. Scand. 138 (2) (2018) 130–136.

I.B. Bruinsma, et al., Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS, J. Neuroimmunol 141 (1) (2020) 235.

M.S. Sedeq, et al., Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity, J. Neurol. Sci. 403 (2019) 92–96.

M.S. Mohamed, et al., Micro-RNA 18b and interleukin 17A profiles in multiple sclerosis patients, Acta Neurol. Scand. 138 (2) (2018) 130–136.

I.B. Bruinsma, et al., Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS, J. Neuroimmunol 141 (1) (2020) 235.

M.S. Sedeq, et al., Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity, J. Neurol. Sci. 403 (2019) 92–96.